Negative Regulation of FcεRI-mediated  Degranulation by CD81 by Fleming, Tony J. et al.
 
1307
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/97/10/1307/08 $2.00
Volume 186, Number 8, October 20, 1997 1307–1314
http://www.jem.org
 
Negative Regulation of Fc
 
e
 
RI-mediated 
Degranulation by CD81
 
By Tony J. Fleming, Emmanuel Donnadieu, Chang Ho Song,
Francois Van Laethem, Stephen J. Galli, and Jean-Pierre Kinet
 
From the Departments of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical 
School, Boston, Massachusetts 02215
 
Summary
 
Signaling through the high affinity receptor for immunoglobulin E (Fc
 
e
 
RI) results in the coor-
dinate activation of tyrosine kinases before calcium mobilization. Receptors capable of interfer-
ing with the signaling of antigen receptors, such as Fc
 
e
 
RI, recruit tyrosine and inositol phos-
phatases that results in diminished calcium mobilization. Here, we show that antibodies
recognizing CD81 inhibit Fc
 
e
 
RI-mediated mast cell degranulation but, surprisingly, without
affecting aggregation-dependent tyrosine phosphorylation, calcium mobilization, or leuko-
triene synthesis. Furthermore, CD81 antibodies also inhibit mast cell degranulation in vivo as
measured by reduced passive cutaneous anaphylaxis responses. These results reveal an unsus-
pected calcium-independent pathway of antigen receptor regulation, which is accessible to en-
gagement by membrane proteins and on which novel therapeutic approaches to allergic dis-
eases could be based.
 
C
 
rosslinking of high affinity receptor for immunoglob-
ulin E (Fc
 
e
 
RI)
 
1
 
–IgE complexes on mast cells and ba-
sophils by multivalent antigens initiates a signaling cascade
characterized by tyrosine kinase activation, calcium release
and influx and, later, by degranulation and release of in-
flammatory mediators (1–5). Like the B and T cell antigen
receptors, Fc
 
e
 
RI lacks endogenous signaling capacity and
uses tyrosine phosphorylation to recruit signaling effector
molecules. Receptor aggregation leads to phosphorylation
and/or activation of several protein tyrosine kinases
(PTKs), Lyn, Syk, Btk, Itk, Fer, and FAK (1–4, 6–8), as
well as protein kinase C isoenzymes (9), MAP kinase (10),
and other signaling molecules such as Cbl and Shc (11, 12).
The precise role of many of these proteins in degranulation
remains undefined. However, it is clear that Fc
 
e
 
RI-medi-
ated calcium mobilization, degranulation, and leukotriene
and cytokine synthesis depend on early tyrosine kinase acti-
vation events, especially the activation of the PTK Syk.
Fc
 
e
 
RI signaling is initiated by tyrosine phosphorylation of
immunoreceptor tyrosine-based activation motifs (ITAM;
defined by the sequence [D/E]x
 
2
 
Yx
 
2
 
Lx
 
6–7
 
Yx
 
2
 
[L/I]; refer-
ences 13, 14), found in Fc
 
e
 
RI
 
b
 
 and FcR
 
g
 
 chains upon re-
ceptor aggregation (1, 3, 4). The primary function of
Fc
 
e
 
RI
 
b
 
 is to amplify FcR
 
g
 
 signals, as it has no autonomous
signaling capacity (4). Phosphorylated ITAMs facilitate
binding of src homology (SH) domain–containing proteins
to Fc
 
e
 
RI (15, 16). The dimeric FcR
 
g
 
 phosphorylated
ITAMs bind Syk via its tandem SH2 domains, leading to
Syk phosphorylation and activation (3, 4, 15, 16). The im-
portance of Syk recruitment to calcium mobilization, de-
granulation, and leukotriene synthesis has been demonstrated
in mast cells lacking Syk expression or by introduction of
dominant negative Syk proteins. Fc
 
e
 
RI-mediated calcium
mobilization and degranulation are absent in Syk-negative
mast cells despite the Fc
 
e
 
RI-mediated tyrosine phosphoryla-
tion of receptor subunits (17). In addition, expression of ki-
nase-inactive Syk blocks Fc
 
e
 
RI-induced calcium release
from endoplasmic reticulum (ER) stores (3) and introduction
of kinase-negative Syk SH2 domains inhibits both degranula-
tion and leukotriene release in Fc
 
e
 
RI-stimulated cells (18).
In addition to activation events, receptor-activated PTKs
initiate the regulation of antigen receptor signaling by
phosphorylating tyrosine-based motifs on membrane recep-
tors known as inhibitory receptors (19, 20). These proteins
bind SH2-containing tyrosine phosphatases (SHP-1 and
SHP-2), and the polyphosphatidylinositol (3,4,5) 5
 
9
 
 phos-
phatase (SHIP), upon coengagement with antigen or growth
factor receptors. Although the molecular targets are still be-
ing defined, phosphatase recruitment to inhibitory recep-
 
1
 
Abbreviations used in this paper:
 
 DNP–HSA, DNP–human serum albumin;
ER, endoplasmic reticulum; Fc
 
e
 
RI, high affinity receptor for IgE; Fc
 
g
 
-
RIIbl, low affinity receptor for IgG; ITAM, immunoreceptor tyrosine-based
activation motif; ITIM, immunoreceptor tyrosine-based inhibitory motif;
KIR, killer cell inhibitory receptor; LTC4, leukotriene C4; PCA, passive cu-
taneous anaphylaxis; PTK, protein tyrosine kinase; RBL-2H3, rat basophilic
leukemia cell line; SH, Src homology; SHIP, SH2-domain–containing poly-
phosphatidylinositol (3,4,5) 5
 
9
 
 phosphatase; SHP-1/SHP-2, SH2-domain–
containing phosphatase-1 or -2; TM4SF, transmembrane 4 superfamily.
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tors has one of two general effects on signaling. Engage-
ment of inhibitory receptors that preferentially bind SHIP,
such as the low affinity receptor for IgG (Fc
 
g
 
RIIb1; refer-
ences 21, 22), results in selective inhibition of calcium in-
flux with little or no effect on receptor-mediated calcium
release or tyrosine phosphorylation. On the other hand,
killer cell inhibitory receptors (KIR) bind SHP-1 upon re-
ceptor costimulation, resulting in reduced tyrosine phos-
phorylation, calcium release from the ER, and calcium in-
flux (23, 24). In both mechanisms, calcium mobilization is
inhibited along with downstream signaling events.
In this report, we isolated mAbs that inhibited Fc
 
e
 
RI-
induced mast cell degranulation. Through protein isolation,
peptide sequencing, cloning, and gene expression, we have
identified CD81 as a novel inhibitory receptor for Fc
 
e
 
RI.
Anti-CD81 mAbs also inhibited passive cutaneous anaphy-
laxis (PCA) reactions, a model of IgE-dependent, mast cell
activation in vivo.
 
Materials and Methods
 
Cell Culture, Reagents, and Antibodies.
 
The rat basophilic leuke-
mia cell line (RBL-2H3) was cultured in Eagle’s minimum essen-
tial medium supplemented with 16% heat-inactivated FCS, 2 mM
 
l
 
-glutamine, and penicillin (100 U/ml)/streptomycin (50 
 
m
 
g
ml
 
2
 
1
 
) (Biofluids, Rockville, MD). NS-1 myeloma cells were cul-
tured in RPMI-1640 supplemented with 20% FCS, glutamine,
and antibiotics. C1.MC/C57.1 cells were cultured as described
(25). DNP–human serum albumin (DNP–HSA) (30–40 mol
DNP/mol albumin) was purchased from Sigma Chemical Co.
(St. Louis, MO). DNP-specific IgE supernatants were used to sat-
urate Fc
 
e
 
RI as described (26). For PCA experiments, MOPC 31c
(IgG1) and anti-DNP mouse IgE (clone SPE-7) were purchased
from Sigma Chemical Co. and anti–rat 
 
b
 
2 integrin (anti-LFA-1
 
b
 
,
CD18; clone WT.3) was purchased from PharMingen (San Di-
ego, CA). MOPC 31c and anti-DNP IgE were dialyzed to re-
move sodium azide before in vivo injections. Anti–rat CD81
(5D1, IgG1) was purified from ascites on protein G–Sepharose
(Pharmacia, Uppsala, Sweden).
 
Production of Anti-RBL-2H3 Antibodies and Flow Cytometry.
 
Spleens from BALB/c immunized with whole RBL-2H3 cells were
fused with NS-1 myeloma cells and plated onto normal BALB/c
spleen feeder cells. To enhance the development of the hybrido-
mas, 
 
Saccharomyces typhimurium
 
 mitogen (Ribi ImmunoChem Re-
search, Inc., Hamilton, MT) was included in the culture medium
from days 0–10. Hybridoma supernatants were tested after day 14
by flow cytometry for binding to RBL-2H3 using FITC-conjugated
goat anti–mouse F(ab
 
9
 
)
 
2
 
-specific antibody (Jackson ImmunoRe-
search Laboratories, Inc., West Grove, PA) and analyzed by flow
cytometry on a FACScan
 
Ò
 
 flow cytometer (Becton Dickinson, San
Jose, CA). From three separate fusions, a total of 2,160 wells were
plated and 622 supernatants from wells with hybridoma growth
were screened by FACS
 
Ò
 
 for reactivity with RBL-2H3 cells. In
all, 283 of 622 (45%) elicited detectable reactivity by FACS
 
Ò
 
 with
membrane antigens of RBL-2H3 (data not shown). The screen-
ing of RBL-2H3–reactive mAbs by serotonin release assay lead to
the identification of 1A12 (IgG2b) and 5D1 (IgG1), which were
characterized further. Rat CD81 transfectants of C1.MC/C57.1
cells were stained with purified 1A12 and 5D1 (1 
 
m
 
g/10
 
6
 
 cells),
counterstained with goat anti–mouse F(ab
 
9
 
)
 
2
 
-specific antibody, and
analyzed by flow cytometry on a FACScan
 
Ò
 
 flow cytometer.
 
Serotonin Release and Leukotriene C4 Assays.
 
RBL-2H3 cells were
loaded with [
 
3
 
H]5-hydroxytryptamine ([
 
3
 
H]serotonin; 0.3 
 
m
 
Ci/
10
 
5
 
 cells) and saturated with DNP-specific IgE in 96-well micro-
titer tissue culture plates (10
 
5
 
 cells well 
 
2
 
1
 
, 37
 
8
 
C, 5% CO
 
2
 
) as de-
scribed (27, 28). Monolayers were washed three times with buffer
(glucose–saline, Pipes buffer (pH 7.2) containing (in mM) 25
Pipes, 110 NaCl, 5 KCl, 5.6 glucose, 0.4 MgCl
 
2
 
, 1 CaCl
 
2
 
, and
0.1% BSA; and 25 
 
m
 
l of a dilution of purified antibody was added
to the monolayers and plates were incubated for 30 min (or as in-
dicated) at room temperature. Triggering of Fc
 
e
 
RI was performed
by the addition of DNP–HSA (final concentration 10–250 ng
ml
 
2
 
1
 
) and plates were incubated at 37
 
8
 
C (30 min except as indi-
cated in Fig. 1 
 
D
 
) with control samples present on each plate. De-
granulation was stopped by placing the plates on ice and by the
addition of 150 
 
m
 
l of cold culture medium/well. 100-
 
m
 
l aliquots
were taken from replicate wells for scintillation counting. Total
cellular incorporation was determined from 1% SDS, 1% NP-40
lysates.
Leukotriene C4 was measured from 10
 
6
 
 anti-DNP IgF-satu-
rated RBL-2H3 treated with 1 
 
m
 
g 5D1 or buffer before trigger-
ing with 30 ng ml
 
2
 
1
 
 DNP–HSA. Supernatants were stored at
 
2
 
80
 
8
 
C until measurement of LTC
 
4
 
 by specific enzyme immu-
noassay (Cayman Chemical, Ann Arbor, MI).
 
Immunoaffinity Chromatography, Electrophoresis, and Western Blot-
ting.
 
RBL-2H3 cells were cultured in routine culture medium
in spinner flasks to a cell density of 
 
z
 
10
 
6
 
/ml, harvested by cen-
trifugation, and washed twice with cold PBS. Washed cells (10
 
10
 
RBL-2H3 cells were obtained from spinner flasks [12 l]) were ex-
tracted in 0.5 M K
 
2
 
HPO
 
4
 
 (pH 7.5) with proteinase inhibitors (10
 
m
 
g/ml pepstatin, 5 
 
m
 
g/ml leupeptin, and 10 
 
m
 
g/ml aprotinin) at
5.0 
 
3
 
 10
 
7
 
 ml
 
2
 
1
 
 (60 min, 4
 
8
 
C) with frequent mixing. 
 
n
 
-octylglu-
coside (10 mM) was added during the extraction to ensure pro-
tein solubility. Postnuclear lysates were prepared by centrifuga-
tion at 15,000 
 
g
 
 (20 min, 4
 
8
 
C), desalted, and passed several times
over protein G–Sepharose coupled to 1A12 (2 mg ml
 
2
 
1
 
 bed vol-
ume), washed with PBS (10 mM 
 
n
 
-octylglucoside), and eluted
with 0.2 M glycine (pH 2.3). Tris-neutralized, concentrated ex-
tracts were reduced with 
 
b
 
-mercaptoethanol, resolved on 12.5%
preparative SDS-PAGE, and transferred to Immobilon
 
S
 
Q
 
 (Milli-
pore, Bedford, MA). The membrane was stained with amido
black and the M
 
r
 
 25-kD band was excised, eluted, alkylated, and
digested overnight with Lys-C. Peptides were separated by re-
verse phase-HPLC and the peptide peak eluting at 36 min was se-
quenced.
For antiphosphotyrosine Western blots, 0.5% Triton X-100
(BBS, proteinase inhibitors) extracts were immunoprecipitated
overnight with 2 
 
m
 
g of antiphosphotyrosine mAb 4G10 bound to
protein A–Sepharose beads (4
 
8
 
C with rotation). Beads were
washed with lysis buffer, eluted, resolved on 12.5% SDS-PAGE,
transferred to nitrocellulose membrane, and immunoblotted with
1 
 
m
 
g ml
 
2
 
1
 
 4G10 mAb followed by incubation with HRP-conju-
gated anti–mouse IgG secondary antibodies and development
with chemiluminescence substrates (Renaissance, Dupont/New
England Nuclear, Boston, MA).
 
Construction and Screening of RBL-2H3 cDNA Library in UNI-
ZAP
 
Ô
 
.
 
Poly (A)
 
1
 
 messenger RNA was isolated from RBL-2H3,
reverse-transcribed into cDNA, size-fractionated on Sephacryl S-500
spin columns, and ligated into UNI-ZAP–XR lambda vector ac-
cording to the instructions of the manufacturer (Stratagene, La Jolla,
CA). After rescue of the cDNA inserts and appropriate restriction
enzyme digests, it was determined that 96% of the plamids con-
tained inserts, with an average size of 1.7 kB. 5 
 
3
 
 10
 
5
 
 plaques were
screened with 
 
32
 
P-labeled mouse CD81 cDNA probe. After hybrid- 
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ization, nitocellulose filters were washed one time with 2
 
3
 
 SSC
containing 0.1% SDS (room temperature) and three times with 0.5
 
3
 
SSC containing 0.1% SDS at 508C. Filters were autoradiographed
and plaques picked and eluted. Candidate plaques were subjected
to three additional rounds of plaque purification before rescue the
cDNA inserts into pBluescript. Sequencing was performed on eleven
isolates and all were found to align with EMBL/GenBank/DDBJ
accession number U19894 isolated from rat brain (29–31).
Transfections. Rat CD81 cDNA from two isolates was sub-
cloned into the pBJ1neo expression vector (4) and 20 mg of etha-
nol-precipitated DNA was used for electroporation of C1.MC/
C57.1 cells (1,050 mF, 270 V). Selection of stable transfectants
was initiated 48 h later by replating at 500–10,000 cells/well with
2 mg/ml G418 (GIBCO BRL, Gaithersburg, MD).
Confocal Microscopy. After overnight adherence and saturation
of FceRI with DNP-specific IgE, RBL-2H3 cells were washed
with buffer and incubated with 3 mM fluo3/AM (Molecular
Probes, Eugene, OR) and 0.2 mg/ml Pluronic (Molecular Probes)
at 378C for 30 min (5% CO2) in a buffer containing 140 mM
NaCl, 5 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 10 mM glucose,
and 1 mM Na-Hepes (pH 7.4). Dye-loaded cells were then
washed once with the same buffer before preincubation (30 min,
room temperature) with buffer (6 5D1, 1 mg/chamber/105 cells)
and triggering with 100 ng/ml DNP–HSA. Ca21 measurements
in single cells were monitored using a laser-scanning confocal mi-
croscope (LSM4, Zeiss, New York) equipped with an argon/kry-
ton laser to excite the dye at 488 nm. Fluorescence emission
above 510 nm was measured after placing a long pass filter in
front of the photomultiplier tube. The confocal system was used
in slow scan mode and fluorescence images were collected every
5 s. Fluo-3 fluorescence measurements were normalized by divid-
ing the average fluorescence intensity (F) occurring during the
course of the experiment to the average fluorescence intensity de-
termined at the beginning of the experiment (F0). All measure-
ments were performed at 22–248C.
Passive Cutaneous Analphylaxis in Rats. Male Wistar rats (275–
300 g) were used in these experiments. Rats were first anesthe-
tized with ether, back skin hair was shaved, and rats were injected
intradermally with 50 ml containing 100 ng anti-DNP IgE or 25
ng anti-DNP–IgE mixed with 50 mg of MOPC 31c (mouse
IgG1, specificity unknown) or 5D1 (mouse IgG1; anti–rat
CD81). Control sites received buffer alone (PBS containing 10
mg/ml21 mouse serum albumin; Sigma Chemical Co). Sites were
marked on the skin for orientation and rats that received 100 ng
anti-DNP injections received a second injection 21 h later with
50 mg of 5D1 or anti–rat LFA-1b (CD18; mouse IgG1) into pre-
viously injected sites. Sites receiving IgE and IgG1 were injected
in triplicate on the same rat. 24 h after IgE injections animals re-
ceived 1 ml of 1 mg/ml DNP–HSA containing 1% Evan’s blue
dye injected intravenously under ether anesthesia. 30 min after
intravenous injection, rats were killed and punch biopsies (2.5
cm2) were obtained, minced, and extracted three times with hot
formamide (808C, 3 h) (32). Pooled samples from tissue sites were
centrifuged and absorbance at 610 nm was measured. A610 values
were converted to micrograms of Evan’s blue dye based on a
standard curve of dilutions of Evan’s blue in formamide.
Results and Discussion
To identify membrane proteins capable of regulating
FceRI signaling, we produced mAbs to the rat basophilic
leukemia (RBL-2H3) cell line and identified antibodies
that inhibited FceRI-mediated degranulation. As shown in
Fig. 1 A, pretreatment of anti-DNP IgE-saturated RBL-
2H3 cells with purified mAb 5D1 inhibited FceRI-medi-
ated degranulation by 75% as measured by release of gran-
ule-stored [3H] serotonin. Blockage of serotonin release
was significant (*, P ,0.05) even at subsaturating concen-
trations of 5D1 (2.5 ng mAb/105 cells; Fig. 1 A; data not
shown). 5D1-mediated inhibition was specific for FceRI
signaling as degranulation induced by PMA and calcium
ionophore ionomycin was unaffected (Fig. 1 B). Further-
more, maximal inhibition of FceRI-mediated degranula-
tion by mAb 5D1 required only brief periods of preincuba-
tion (Fig. 1 C) and inhibition was sustained for at least 1 h
of antigen stimulation (Fig. 1 D).
Next, we sought to identify the protein recognized by
the degranulation–inhibitory 5D1 mAb. 5D1 and a second
degranulation–inhibitory mAb (designated 1A12) recog-
nized proteins of Mr 25 kD (Fig. 2 A; data not shown).
5D1 and 1A12 blocked each others’ binding to RBL-2H3
cells, although neither mAb inhibited IgE binding and,
Figure 1. Effect of preincubation of purified mAb 5D1 on FceRI-
mediated degranulation in RBL-2H3 cells. (A–D) Degranulation of IgE-
saturated, RBL-2H3 cells after incubation with buffer (closed circles) or pu-
rified 5D1 mAb (mouse IgG1) at 2.5 ng (closed squares), 25 ng (closed trian-
gles), or 50 ng (closed inverted triangles) (A, C, D) or with 100 ng (B) of 5D1
mAb per 105 cells before triggering with the indicated concentrations of
DNP–HSA (A), 50 ng/ml21 DNP–HSA (C and D), or with PMA and
ionomycin (B). Cells were preincubated with 5D1 or buffer for 30 min
(A, B, D) or for the indicated times (C) at room temperature before trig-
gering for 30 min (A–C; 378C, 5% CO2) or as indicated (D). The data
shown are representative of .10 experiments with the 5D1 mAb. Data
are expressed as mean dpm 6 standard deviation or as percentages of con-
trol (no antibody) mean dpm. Statistical significance versus untreated con-
trols was determined using an unpaired Student’s t test: *, P ,0.05; **, P
,0.01; ***, P ,0.001 for A. All data points in C and D were found to be
significantly different from controls (P ,0.02) with the exception of the
5-min preincubation time point with 2.5 ng mAb 5D1 (C, P 5 0.067).1310 Negative Regulation of FceRI-mediated Degranulation by CD81
conversely, saturation of FceRI with IgE had no effect on
1A12 binding (data not shown), suggesting that (a) 1A12
and 5D1 recognized the same protein (see Fig. 2 C) and (b)
FceRI and the 1A12/5D1 antigen were not colocalized on
the cell membrane. Because mAb 1A12 was more effective
at immunoprecipitation and on Western blots, it was used
for protein purification. Batch preparations of RBL-2H3
extracts were immunoprecipitated with mAb 1A12, re-
solved on preparative SDS-PAGE, and transferred to nitro-
cellulose for protein sequencing. In Fig. 2B, peptide sequence
obtained from Lys-C digests of 1A12 immunoprecipitates is
shown aligned with homologous sequences from mouse
and human CD81. Based on these data, we cloned rat
CD81 from a RBL-2H3 cDNA library using mouse CD81
cDNA as a probe and expressed the cDNA in the mouse
mast cell line C1.MC/C57.1 (25). As shown in Fig. 2 C,
both degranulation–inhibitory mAbs 1A12 and 5D1 recog-
nized rat CD81.
CD81 belongs to the transmembrane 4 superfamily
(TM4SF) which includes CD9, CD53, CD63, and CD82
(33). It is broadly expressed on hematopoietic cells (T and
B lymphocytes, granulocytes, monocytes) and on some
nonlymphoid tumors. The function of CD81 (or other
TM4SF proteins) is incompletely understood although
CD81 appears to modulate the signaling of other mem-
brane receptors. CD81 is found in the CD19–CD21 com-
plex on B cells and mAbs to CD81 or CD19 have been re-
ported to reduce the threshold for B cell receptor signaling
(34) and enhance B cell adhesion via VLA4 (35). Consis-
tent with a costimulatory role in B cell receptor signaling,
CD81 2/2 mice express lower levels of CD19 on B cells,
which is proposed to contribute to a defect in humoral im-
munity (36). For T lineage cells, both stimulatory and in-
hibitory activities for anti-CD81 mAbs have been reported
Figure 2. Characterization and isolation of rat CD81. (A) Western blot of 5 3 105 cell equivalents from Triton X-100 extracted RBL-2H3 cells im-
munoblotted with 1 mg/ml 1A12 mAb. (B) 1A12 immunoprecipitates from 1010 RBL-2H3 cells were digested with Lys-C and purified by HPLC. 1A12
peptide sequence is shown aligned with homologous sequences from mouse and human CD81. (C) Expression of rat CD81 in mouse mast cell line
C1.MC/C57.1 (25) and FACSÒ staining with 5D1 and 1A12 mAbs. Rat CD81 was isolate from a RBL-2H3 cDNA library screened with mouse CD81
cDNA (provided by Dr. S. Levy, Stanford University, Stanford, CA). Two rat CD81 isolates were cloned into the pBJ1neo expression vector (4) and
transfected into C1.MC/C57.1 cells by electroporation with identical results. FACSÒ profiles of C1.MC/C57.1 transfectant 5A12 stained mAbs 1A12
and 5D1 are shown.
Figure 3. CD81 mAbs fail to inhibit FceRI-induced tyrosine phosphor-
ylation, calcium mobilization, and leukotriene synthesis. (A) Phosphoty-
rosine Western blot of antiphosphotyrosine immunoprecipitates from
FceRI-triggered RBL-2H3 cells without (lanes 2–4) or with (lanes 5–7)
pretreatment with anti-CD81 mAb 5D1. (B) Effect of anti-CD81 on cal-
cium mobilization of fura-2–loaded RBL-2H3 cells triggered through
FceRI as measured by confocal microscopy. Fluo-3 fluorescence mea-
surements were normalized by dividing the average fluorescence intensity
(F) occurring during the course of the experiment to the average fluores-
cence intensity at the beginning of the experiment (F0) and expressed as
F/F0. Traces are shown of 10 individual cells (thin lines) together with
mean values for these cells (thick lines) and represent typical results ob-
tained from five separate experiments. (C) [3H]serotonin release from
RBL-2H3 cells prepared as in confocal microscopy measurements except
that 3 mCi/ml [3H]serotonin was added to cultures. Release was mea-
sured as in Fig. 1. (D) LTC4 measurements from 106 anti-DNP IgE satu-
rated RBL-2H3 treated with 1 mg 5D1 (open squares) or buffer (open circles)
before triggering with 30 ng/ml DNP–HSA for the indicated periods of
time.1311 Fleming et al.
(37–40). CD81 ligation enhances IL-4 production from
antigen-specific CD41 T cells (37), and integrin activation
and IL-2–dependent proliferation in human thymocytes
(38). Alternatively, CD81 was originally called TAPA-1
(target of antiproliferative antibody) based on inhibition of
proliferation in human T cell lines by CD81 antibodies
(39). Some of these pleiotropic effects may stem from the
potential signaling molecules with which CD81 has been
reported to associate, including CD4, CD8, MHC class II,
other TM4SF proteins, integrin VLA4, and phosphatidyl-
inositol 4 kinase (33, 41–44).
To target the site of CD81 inhibition of degranulation,
we next examined the effect of CD81 antibodies on the
earliest events of FceRI signal transduction, i.e., tyrosine
phosphorylation of proteins by activated, nonreceptor ty-
rosine kinases including Lyn and Syk, and calcium mobili-
zation (1–4). In these experiments, IgE-saturated RBL-
2H3 cells were pretreated with purified anti-CD81 before
triggering with DNP–HSA for the indicated periods of
time, followed by extraction and immunoprecipitation of
total tyrosine-phosphorylated proteins. As shown in Fig. 3
A, no major changes in the pattern of FceRI-induced ty-
rosine phosphorylation were detected with anti-CD81
treatment before antigen triggering. Although not shown
in Fig. 3 A, incubation of RBL-2H3 cells with 5D1 alone
(no antigen triggering) did not induce detectable tyrosine
phosphorylation. This observation in RBL-2H3 cells con-
trasts with anti-CD81–induced tyrosine phosphorylation
induced in B cells, the latter probably signaling through the
CD19–CD21 complex (45).
The effect of anti-CD81 on FceRI-induced calcium
mobilization was monitored on individual, adherent RBL-
2H3 cells by confocal microscopy in cells loaded with cal-
cium dye fluo-3. As shown in Fig. 3 B, no inhibition of
FceRI-induced calcium mobilization in anti-CD81–treated
versus controls was observed by confocal microscopy, de-
spite inhibition of degranulation under these conditions
(Fig. 3 C). Anti-CD81 pretreatment had no effect on cal-
cium release from intracellular stores in cells triggered in
Ca21-free buffer containing 0.5 mM EGTA or on pretrig-
gering baseline values (data not shown). Similar results
were also obtained with RBL-2H3 triggered through
FceRI in suspension using a spectrophotometer (data not
shown). In separate experiments, anti-CD81 mAb 5D1 did
not inhibit leukotriene C4 (LTC4) production induced by
DNP–HSA/IgE stimulation (Fig. 3 D). LTC4 production
is dependent on activation of phospholipase A2 (tyrosine
kinase and calcium dependent) and is regulated by PMA-
sensitive, protein kinase C isozymes (46, 47). These data
suggest that CD81 acts independently of early tyrosine
phosphorylation and calcium mobilization events that are
critical for mast cell degranulation.
These results were unexpected in light of the reported
modes of action of other inhibitory receptors. These pro-
teins fall into two major classes: type I, transmembrane pro-
teins that are members of the Ig superfamily (FcgRIIb1,
KIR, CTLA-4, CD22, gp49b1, paired Ig-like receptors,
signal-regulatory proteins) and type II, transmembrane,
C-type lectins (e.g., Ly-49, NKG2A, mast cell function–
associated protein) (21–23, 48–55). Inhibitory receptors share
a cytoplasmic motif, the immunoreceptor tyrosine-based
inhibitory motif (ITIM consensus sequence V/Ix2Yx2I/L;
references 20, 48), which is a target for tyrosine phosphor-
ylation during receptor activation. Phosphorylated ITIMs
bind the phosphatases SHP-1, SHP-2, or SHIP, and physi-
cal associations with these phosphatases and/or functional
evidence of these associations (tyrosine dephosphorylation
and/or decreased calcium mobilization) have been demon-
strated in all inhibitory receptors that have been character-
ized (21–23, 48, 49, 52–54).
Figure 4. Inhibition of passive cutaneous anaphylaxis in Wistar rats by
anti-CD81. Male Wistar rats were injected intradermally with (A) 25 ng
DNP-specific IgE mixed with 50 mg anti-CD81 mAb 5D1 (mouse IgG1)
or control mouse IgG1 mAb (MOPC 31c; specificity unknown) or (B)
100 ng DNP-specific IgE alone. Mice receiving 100 ng IgE alone were
reinjected 21 h later with buffer, 5D1, or a mouse IgG1 control mAb to
LFA-1b chain (anti-CD18; WT.3). Control sites (no IgE) received buffer
or 50 mg of IgG1 subclass mAb. 24 h after IgE injections, 1 mg of antigen
(DNP–HSA; 1 mg/ml in PBS containing 1% Evan’s blue dye) was in-
jected intravenously and rats were killed 30 min later. Extravasation of
Evan’s blue dye into the skin was quantified by A610 measurements of se-
rial hot formamide extractions (54) of minced punch biopsies (2.5 cm2/
site). Sample A610 values were converted to micrograms of Evan’s blue dye
based on standard curves of Evan’s blue A610 absorbance in formamide.
Results taken from three injected sites per condition (IgE plus buffer or
antibody) or a single site (IgG1 controls without IgE) from a single rat and
expressed as mean micrograms of Evan’s blue dye 6 standard deviation.
Comparable results were obtained on two additional rats for both experi-
ments shown. Statistical significance was determined using an unpaired
Student’s t test: *, P ,0.05; **, P ,0.01 (actual values: A, P 5 0.024 ver-
sus MOPC 31c controls; B, P 5 0.009 versus anti-LFA-1b controls).1312 Negative Regulation of FceRI-mediated Degranulation by CD81
CD81 differs from these inhibitory receptors in three
important ways. First, unlike other inhibitory receptors,
CD81 inhibits FceRI-mediated degranulation while leav-
ing both tyrosine phosphorylation and calcium mobiliza-
tion apparently unaffected. Although these results cannot
exclude a very selective inhibition of kinase activity by
CD81 antibodies, it is clear that no detectable effect is
found on tyrosine kinase–sensitive calcium mobilization or
LTC4 production. Second, CD81 belongs to a different
structural class of proteins than the other inhibitory recep-
tors. CD81 is a TM4SF protein with four transmembrane
spanning segments, two extracellular loops, two short cyto-
plasmic tails, and a short intracellular loop between trans-
membrane segments 2 and 3 (33). Third, the cytoplasmic
tails of CD81 lack ITIM motifs. Although there is an
ITIM-like sequence (GCYGAI) in the short intracellular
loop between transmembrane segments 2 and 3, there is no
evidence that this site is phosphorylated by tyrosine kinases
or capable of binding to SH2 domains.
To assess the activity of anti-CD81 in FceRI signaling in
normal mast cells, we chose the PCA model, a classical sys-
tem for studying mast cell activation in vivo (32, 56). In
these experiments, rats were injected intradermally with
anti-DNP IgE mixed with anti-CD81 mAb 5D1 (IgG1) or
with class-matched mouse IgG1 as controls (Fig. 4 A). Ad-
ditional rats received anti-DNP IgE alone into the skin at
time 0, followed by a second injection (buffer, 5D1, or
anti–rat LFA-1b [IgG1]) (Fig. 4 B) into IgE-injected sites
21 h after IgE injections. 24 h after IgE priming, rats re-
ceived 1 mg of antigen intravenously (DNP–HSA contain-
ing 1% Evan’s blue dye). Mast cell activation through
FceRI in PCA results in the release of several vasoactive
substances, which act to increase vascular permeability, a
property that is quantified by local accumulation of the
Evan’s blue dye from the vasculature into the sites of IgE
injections. These results are expressed as micrograms of
Evan’s blue dye converted from A610 measurements of for-
mamide-extracted tissue biopsies (32). As shown in Fig. 4
A, coinjection of anti-CD81 mAb 5D1 during IgE priming
significantly inhibited IgE-dependent PCA reactions (P 5
0.024) compared with class-matched controls. To limit the
possibility of nonspecific suppression of PCA reactions due
to tissue deposition of IgG1 mAbs, we repeated these ex-
periments by injecting anti-CD81 mAb 5D1 or anti-LFA-
1b (CD18) into the IgE-injected sites 3 h before antigen ad-
ministration. LFA-1b is expressed on mast cell lines including
RBL-2H3, whereas anti-LFA-1b has no effect on FceRI-
mediated degranulation in RBL-2H3 cells (57; data not
shown). Similar to coinjection of IgE and IgG1 mAbs, sep-
arate injections of anti-CD81 yielded significant inhibition
of PCA reactions compared with anti-LFA-1b controls
(Fig. 4 B).
In conclusion, we have demonstrated that CD81 is a
novel inhibitory receptor for FceRI. The observation that
CD81 acts on calcium-independent events required for
mast cell degranulation distinguishes CD81 from previously
described inhibitory receptors, such as FcgRIIb1 and KIR,
that act upstream of calcium influx. Anti-CD81 mAbs also
inhibited IgE-dependent PCA reactions, which suggests
the CD81 pathway is present in normal mast cells and ca-
pable of being engaged to inhibit mast cell responses in
vivo. Therefore, the pathway engaged by CD81 is a candi-
date for therapeutic strategies aimed at intervention of al-
lergic responses.
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